

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office. Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/425,501	10/22/1999	ROBERT MARK	GNN-005	9642
25291	7590 11/16/2001			
AMERICAN HOME PRODUCTS CORPORATION FIVE GIRALDA FARMS PATENT LAW			EXAMINER	
			CHUNDURU, SURYAPRABHA	
MADISON, N	IJ 07940		ART UNIT	PAPER NUMBER
			1656	6
		•	DATE MAILED: 11/16/2001	The state of the s

Please find below and/or attached an Office communication concerning this application or proceeding.

•						
; .		Application No.	Applicant(s)			
•		09/425,501	MARK ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Suryaprabha Chunduru	1656			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHO THE M - Exten after - If the - If NO - Failur - Any re	ORTENED STATUTORY PERIOD FOR REPL'MAILING DATE OF THIS COMMUNICATION. Isions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a repl period for reply is specified above, the maximum statutory period or re to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply by within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS to cause the application to become ABAND	e timely filed days will be considered timely. from the mailing date of this communication. DNED (35 U.S.C. § 133).			
1)⊠	Responsive to communication(s) filed on 26 s	September 2001 .				
2a)⊠	This action is FINAL . 2b) Th	is action is non-final.				
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4) Claim(s) 22-48 is/are pending in the application.						
	4a) Of the above claim(s) 22-42 and 45-48 is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>43 and 44</u> is/are rejected.					
• —	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/o	or election requirement.	•			
	on Papers					
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
a)	1. Certified copies of the priority documen	ts have been received				
	2. Certified copies of the priority document		cation No.			
* 5	3. Copies of the certified copies of the price application from the International Buse the attached detailed Office action for a list	ority documents have been recureau (PCT Rule 17.2(a)).	eived in this National Stage			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
) The translation of the foreign language process. The translation of the foreign language process. The translation is made of a claim for domes.					
Attachmen						
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)			

Application/Control Number: 09/425,501

Art Unit: 1656

DETAILED ACTION

- 1. Applicants' response to the office action (Paper No. 15) filed on September 26, 2001 has been entered.
- 2. Claims 1-4, 14 and 15 were cancelled. New claims 22-48 were added.

Newly submitted claims 22-42, 45-48 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

These claims 22-42, 45-48 would properly be placed in Groups IV-V of the original restriction. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 22-42, and 45-48 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

The claims 43 and 44 are directed to the claims originally elected and are considered for examination in this office action.

New Grounds of Rejection Necessitated by Amendment

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Application/Control Number: 09/425,501

Art Unit: 1656

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 43 and 44 are rejected under 35 U.S.C. 102(b) as being anticipated by Nagase et al. (DNA Research, 3: 321-329, 1996).

Nagase et al. teaches the coding sequence of cDNA clone from human myeloid cell line KG-1 and brain wherein Nagase et al. disclose a cDNA clone constructed from a whole brain mRNA fraction, (cDNA library) which is identical or absolute homology (100%) to the claimed sequences in SEQ ID No. 2 of the instant invention (see sequence alignment from GenEmbl. and Swissprot_39 databases). Nagase et al. also disclose that the cDNA clones showed homology to the genes that play key roles in regulation of developmental stages, apoptosis and cell-to-cell interaction (see page 321, abstract and page 321, column 2, paragraph 1). Thus the disclosure of Nagase et al. meets the limitations in the instant claims 43 and 44.

Response to Arguments

- 4. Applicants response to the office action (Paper No.15) is fully considered and deemed persuasive in part.
- 5. The objection made in the previous office action is withdrawn herein in view of applicants, amendment (Paper No.15).
- 6. The rejection made in the previous office action under U.S.C. 112, first paragraph is withdrawn herein in view of applicant's amendment (Paper No. 15).

Application/Control Number: 09/425,501

Art Unit: 1656

7. Applicant's arguments with respect to the rejection made under U.S.C. 102(b) to claims 1-4, 14 and 15 have been considered but are moot in view of the applicants' amendment and arguments (Paper No. 15) and in view of the new ground(s) of rejection.

No claims are allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suryaprabha Chunduru whose telephone number is 703-305-

Page 4

Application/Control Number: 09/425,501

Art Unit: 1656

1004. The examiner can normally be reached on 8.30A.M. - 4.30P.M, Mon - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on 703-308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-0294 for regular communications and - for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Suryaprabha Chunduru November 9, 2001

JEFFREY FREDMAN
PRIMARY EXAMINES